Amicus Therapeutics Inc. [NASDAQ: FOLD] closed the trading session at $11.48 on 09/09/21. The day’s price range saw the stock hit a low of $11.39, while the highest price level was $11.7177. The company report on September 3, 2021 that Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021.
Amicus Therapeutics (Nasdaq: FOLD) announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 3:30 p.m. E.T.
The stocks have a year to date performance of -50.28 percent and weekly performance of -1.71 percent. The stock has been moved at 6.39 percent over the last six months. The stock has performed 10.17 percent around the most recent 30 days and changed 7.19 percent over the most recent 3-months.
If compared to the average trading volume of 2.13M shares, FOLD reached to a volume of 2058237 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc. [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $17.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Amicus Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 19, 2021. The new note on the price target was released on May 27, 2021, representing the official price target for Amicus Therapeutics Inc. stock. Previously, the target price had yet another raise to $16, while UBS analysts kept a Buy rating on FOLD stock.
The Average True Range (ATR) for Amicus Therapeutics Inc. is set at 0.39, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 11.06. The Price to Book ratio for the last quarter was 14.35, with the Price to Cash per share for the same quarter was set at 1.41.
FOLD stock trade performance evaluation
Amicus Therapeutics Inc. [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.71. With this latest performance, FOLD shares gained by 10.17% in over the last four-week period, additionally plugging by 6.39% over the last 6 months – not to mention a drop of -17.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 63.12, with the RSI for the last a single of trading hit 62.68, and the three-weeks RSI is set at 61.77 for Amicus Therapeutics Inc. [FOLD]. The present Moving Average for the last 50 days of trading for this stock 10.06, while it was recorded at 11.54 for the last single week of trading, and 13.39 for the last 200 days.
Amicus Therapeutics Inc. [FOLD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc. [FOLD] shares currently have an operating margin of -93.47 and a Gross Margin at +84.71. Amicus Therapeutics Inc.’s Net Margin is presently recorded at -106.12.
Return on Total Capital for FOLD is now -34.47, given the latest momentum, and Return on Invested Capital for the company is -39.53. Return on Equity for this stock declined to -72.59, with Return on Assets sitting at -31.88. When it comes to the capital structure of this company, Amicus Therapeutics Inc. [FOLD] has a Total Debt to Total Equity ratio set at 154.25. Additionally, FOLD Total Debt to Total Capital is recorded at 60.67, with Total Debt to Total Assets ending up at 49.83. Long-Term Debt to Equity for the company is recorded at 151.85, with the Long-Term Debt to Total Capital now at 59.72.
Reflecting on the efficiency of the workforce at the company, Amicus Therapeutics Inc. [FOLD] managed to generate an average of -$573,193 per employee. Receivables Turnover for the company is 6.51 with a Total Asset Turnover recorded at a value of 0.30.Amicus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.10 and a Current Ratio set at 4.30.
Earnings per share (EPS) analysis for Amicus Therapeutics Inc. [FOLD] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amicus Therapeutics Inc. go to -1.00%.
Amicus Therapeutics Inc. [FOLD]: Insider Ownership positions
There are presently around $3,186 million, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 24,729,400, which is approximately 1.404% of the company’s market cap and around 1.10% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 23,121,329 shares of the stock with an approximate value of $265.43 million in FOLD stocks shares; and REDMILE GROUP, LLC, currently with $238.78 million in FOLD stock with ownership of nearly -1.491% of the company’s market capitalization.
Positions in Amicus Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 116 institutional holders increased their position in Amicus Therapeutics Inc. [NASDAQ:FOLD] by around 24,211,823 shares. Additionally, 128 investors decreased positions by around 27,783,305 shares, while 43 investors held positions by with 225,508,453 shares. The mentioned changes placed institutional holdings at 277,503,581 shares, according to the latest SEC report filing. FOLD stock had 31 new institutional investments in for a total of 5,407,418 shares, while 54 institutional investors sold positions of 10,743,620 shares during the same period.